TFS Capital’s Arbutus Biopharma ABUS Stock Holding History

TFS Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-14,195	Closed	-$35K	–	642
2016 Q4	$35K	Buy	+14,195	New	+$41.3K	0.01%	702
2016 Q3	–	Sell	-30,860	Closed	-$107K	–	728
2016 Q2	$107K	Sell	30,860 -71,467	-70%	-$302K	0.02%	845
2016 Q1	$423K	Buy	102,327 +55,043	+116%	+$197K	0.06%	508
2015 Q4	$210K	Buy	+47,284	New	+$259K	0.02%	582
2014 Q3	–	Sell	-30,625	Closed	-$400K	–	1025
2014 Q2	$400K	Buy	+30,625	New	+$434K	0.03%	726

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TFS Capital's ABUS Position: Q1 2017 in Review

TFS Capital sold out of Arbutus Biopharma (ABUS) in Q1 2017, closing a stake of 14,195 shares — an estimated $35K sold.

TFS Capital first reported a position in ABUS in Q2 2014 and held it in 5 quarters. The position peaked at $423K in Q1 2016. 53 funds tracked by Wall St. Rank hold ABUS as of Q1 2017.

TFS Capital reported no remaining Arbutus Biopharma position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 14,195 Arbutus Biopharma shares in Q1 2017, an estimated $35K.
TFS Capital first reported a position in Arbutus Biopharma in Q2 2014 and held it in 5 quarters.
TFS Capital's Arbutus Biopharma position peaked at $423K in Q1 2016.
53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.